On Dec. 22, 2025, Novo Nordisk announced announced that the US Food and Drug Administration (FDA) has approved once-daily Wegovy^® pill, the first oral GLP-1 medicine for obesity in the US. Wegovy^® pill is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off. Wegovy^® pill is also indicated to reduce the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke in adults with overweight or obesity and established cardiovascular disease.

“The launch of Wegovy^® in 2021 changed how obesity was viewed and treated in the US. Now, with Wegovy^® pill, we are offering a magnitude of weight loss that no other oral GLP-1 obesity candidate has been able to duplicate in phase 3 trials. We are confident that the expansion of Wegovy^® to a pill will help patients who may have not sought or accepted treatment before,” said Dave Moore, executive vice president, US Operations at Novo Nordisk. “Wegovy^® pill is the next chapter in our decades-long GLP-1 experience—supported by the most affordable self-pay price to date in a GLP-1 for obesity. We are prepared for a full US launch in early January 2026, with manufacturing well underway in our North Carolina facilities.”

The FDA approval of Wegovy^® pill is based on the results from the OASIS 4 phase 3 clinical trial, which was a 64-week medical study that included 307 adults with obesity or overweight with one or more weight-related comorbidities, without diabetes.

Results showed that if all patients stayed on treatment, people taking Wegovy^® pill once-daily along with a reduced calorie diet and exercise achieved an average weight loss of about 17% (16.6%) versus about 3% (2.7%) with placebo.^*1 When looking at the efficacy regardless of if all patients stayed on treatment, an average weight loss of about 14% (13.6%) was achieved by people taking Wegovy^® pill compared to about 2% (2.4%) for placebo.

In OASIS 4, common adverse reactions were similar to those previously seen in clinical trials with Wegovy^® (semaglutide) injection 2.4 mg, including nausea, diarrhea, and vomiting.

The starting dose of 1.5 mg will be available in pharmacies and select telehealth providers in early January with savings offers for just $149 per month. Wegovy^® pill is only approved in the US. Novo Nordisk expects to launch Wegovy^® pill in early January 2026.

Obesity is a serious, chronic, progressive, and complex disease that requires long-term management. One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off. Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.